C12N 2810/851
From growth factors
Official title: from growth factors; from growth regulators
C12N2810/851 (From growth factors) appears on 40 US grants and 58 published applications in this corpus.
Search patents in C12N- Granted patents
- 40
- Published applications
- 58
- Assignees
- 38
- Inventors
- 117
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 3 | 2 |
| 2003 | 4 | 10 |
| 2004 | 4 | 8 |
| 2005 | 1 | 1 |
| 2006 | 3 | 6 |
| 2007 | 2 | 2 |
| 2008 | 3 | 6 |
| 2009 | 1 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 3 |
| 2012 | 1 | 3 |
| 2013 | 0 | 2 |
| 2014 | 1 | 1 |
| 2015 | 1 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 2 |
| 2018 | 2 | 2 |
| 2019 | 2 | 1 |
| 2020 | 2 | 1 |
| 2021 | 0 | 1 |
| 2022 | 1 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 2 |
| 2025 | 0 | 1 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of delivering anionic agents in vivo using non-viral nanoparticle-based delivery systems16 Jun 2026US 12,653,905 B2Nanora Pharma Inc.
- Methods of delivering anionic agents in vivo using non-viral nanoparticle-based delivery systems26 Sep 2023US 11,766,486 B2Nanora Pharma Inc.
- Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors23 Aug 2022US 11,419,926 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Method of making peptide-tagged PEGylated chitosan nanoparticles13 Oct 2020US 10,799,601 B2Nanora Pharma Inc.
- Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells10 Mar 2020US 10,583,200 B2EnGeneIC Molecular Delivery Pty Ltd
- Vectors for delivery of human growth hormone gene and multiple therapeutic genes into central nervous system by crossing blood brain barrier11 Sep 2025US 2025/0281641 A1Usmedigene Inc.
- Co-expression of constructs and immunoinhibitory compounds1 Aug 2024US 2024/0252625 A1Nykode Therapeutics ASA
- Methods of delivering anionic agents in vivo using non-viral nanoparticle-based delivery systems16 May 2024US 2024/0156984 A1Nanora Pharma Inc.
- Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders9 Feb 2023US 2023/0038520 A1Asklepios Biopharmaceutical, Inc.
- Methods of delivering anionic agents in vivo using non-viral nanoparticle-based delivery systems15 Apr 2021US 2021/0106695 A1Nanora Pharma Inc.
Most cited
By later US patents
- Non-invasive gene targeting to the brain83US 6,372,250 B1The Regents of the University of California · 2002
- Receptor-mediated gene delivery using bacteriophage vectors63US 6,054,312 ASelective Genetics, Inc. · 2000
- Compositions and methods for delivery of agents for neuronal regeneration and survival50US 6,551,618 B2King's College · 2003
- Chimeric Gag pseudovirions48US 6,099,847 AThe United States of America as represented by the Department of Health and Human Services · 2000
- Nucleic acid delivery vehicles45US 6,287,857 B1Genzyme Corporation · 2001